You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
羅欣藥業(002793.SZ):注射用谷胱甘肽繼續中標福建帶量採購
格隆匯 03-30 17:07

格隆匯3月30日丨羅欣藥業(002793.SZ)公佈,近日,福建省醫療保障局、福建省衞生健康委員會、福建省藥品監督管理局發佈《關於落實部分國家、省級藥品集中帶量採購協議期滿後接續工作的通知》,公司下屬子公司山東羅欣藥業集團股份有限公司申報的注射用谷胱甘肽中標。

其中,注射用谷胱甘肽(0.6g)採購數量為53.4138萬支,注射用谷胱甘肽(1.2g)採購數量為30.0733萬支,採購區域均為福建省,採購週期為1年。

公司注射用谷胱甘肽2021年度銷售額為1601.09萬元,佔2021年度主營業務收入的比例為0.25%。

該品種上輪福建省集中帶量採購公司中標,該次中標繼續延續了中標資格。公司後續簽訂採購合同並實施後,將有利於進一步擴大中選產品在福建省的銷售,提高中選產品的市場佔有率,提升公司的品牌影響力,對公司的未來經營業績產生積極的影響。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account